A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib, Eric J. Feldman, Jacqueline Greer, Jane L. Liesveld, Laura M. Bruzek, Lawrence Morris, Youn Park, Alex A. Adjei, Scott H. Kaufmann, Elizabeth Garrett-Mayer, Peter L. Greenberg, John J. Wright, Judith E. Karp

Research output: Contribution to journal › Article › peer-review

158 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds